Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion

Prostate

Volumn 72, Issue 16, 2012, Pages 1719-1735

  Hudak, Lukasz ^a   Tezeeh, Patrick ^a   Wedel, Steffen ^a   Makarević, Jasmina ^a   Juengel, Eva ^a   Tsaur, Igor ^a   Bartsch, Georg ^a   Wiesner, Christoph ^a   Haferkamp, Axel ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

cell signaling; HDAC; integrins; interferon alpha; prostate cancer

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTEGRIN; ALPHA3 INTEGRIN; BETA1 INTEGRIN; CELL ADHESION MOLECULE; HISTONE DEACETYLASE; HISTONE H3; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; RECOMBINANT ALPHA2A INTERFERON; SCLEROPROTEIN; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL CYCLE PROGRESSION; CELL MIGRATION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERFERON-ALPHA; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84867871427     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22525     Document Type: Article

References (55)

1. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G,. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604-610.
2. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN,. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177-189.
3. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V,. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem 2004; 48: 273-290.
4. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE,. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828-1835.
5. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ Sr., Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011; 29: 2052-2059.
6. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS,. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 2010; 103: 12-17.
7. Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA,. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011; 28: 479-491.
8. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA,. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 2011; 88: 418-424.
9. Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS,. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL). Invest New Drugs In press.
10. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J,. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon-alpha. Int J Oncol 2002; 20: 97-106.
11. Kuljaca S, Liu T, Tee AE, Haber M, Norris MD, Dwarte T, Marshall GM,. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 2007; 6: 68.
12. Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Saito Y,. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Int J Clin Oncol 2011; 16: 671-678.
13. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA,. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2009; 13: 2376-2385.
14. Engl T, Relja B, Blumenberg C, Müller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA,. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006; 78: 1784-1793.
15. Dillman RO,. Cancer immunotherapy. Cancer Biother Radiopharm 2011; 26: 1-64.
16. Krämer OH, Baus D, Knauer SK, Stein S, Jäger E, Stauber RH, Grez M, Pfitzner E, Heinzel T,. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 2006; 20: 473-485.
17. Wong LH, Sim H, Chatterjee-Kishore M, Hatzinisiriou I, Devenish RJ, Stark G, Ralph SJ,. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J Biol Chem 2002; 277: 19408-19417.
18. Singh RP, Raina K, Deep G, Chan D, Agarwal R,. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009; 15: 613-621.
19. Luszczek W, Cheriyath V, Mekhail TM, Borden EC,. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: Correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther 2010; 9: 2309-23021.
20. Yamaguchi H, Ding Y, Lee JF, Zhang M, Pal A, Bornmann W, Yan DH, Hung MC,. Interferon-inducible protein IFIXalpha inhibits cell invasion by upregulating the metastasis suppressor maspin. Mol Carcinog 2008; 47: 739-743.
21. Zhang Z, Song L, Maurer K, Petri MA, Sullivan KE,. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun 2010; 11: 124-133.
22. Shiraishi T, Watanabe M, Muneyuki T, Nakayama T, Morita J, Ito H, Kotake T, Yatani R,. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 1998; 61: 90-94.
23. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM,. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999; 39: 8-15.
24. Sarkar FH, Li Y, Sakr WA, Grignon DJ, Madan SS, Wood DP Jr, Adsay V,. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 1999; 40: 256-260.
25. Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M,. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int 2006; 97: 644-648.
26. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T, Kawabe K, Sakamoto A, Murakami T, Machinami R,. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 1998; 29: 778-783.
27. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW,. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008; 33: 375-380.
28. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schäfer BW,. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene 2010; 29: 3942-3952.
29. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Tenta R, Koutsilieris M,. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 2005; 19: 911-920.
30. Ribal MJ, Fernandez PL, Lopez-Guillermo A, Farré X, Santos Y, Gibanel R, Cardesa A, Alcaraz A,. Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res 2003; 23: 5101-5106.
31. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ,. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003; 169: 1325-1330.
32. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R,. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008; 7: 1828-1835.
33. Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R,. p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 2009; 69: 1166-1173.
34. Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R,. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther 2006; 319: 533-542.
35. Blaheta RA, Franz M, Auth MK, Wenisch HJ, Markus BH,. A rapid non-radioactive fluorescence assay for the measurement of both cell number and proliferation. J Immunol Methods 1991; 142: 199-206.
36. Blaheta RA, Kronenberger B, Woitaschek D, Weber S, Scholz M, Schuldes H, Encke A, Markus BH,. Development of an ultrasensitive in vitro assay to monitor growth of primary cell cultures with reduced mitotic activity. J Immunol Methods 1998; 211: 159-169.
37. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, Cress AE,. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One 2008; 3: e3535.
38. Engl T, Relja B, Marian D, Blumenberg C, Müller I, Beecken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D, Blaheta RA,. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006; 8: 290-301.
39. Shen X, Falzon M,. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol 2003; 199: 165-177.
40. Rentala S, Yalavarthy PD, Mangamoori LN,. Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J Androl 2010; 12: 548-555.
41. 1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011; 121: 226-237.
42. Pontes-Junior J, Reis ST, Dall'Oglio M, Neves de Oliveira LC, Cury J, Carvalho PA, Ribeiro-Filho LA, Moreira Leite KR, Srougi M,. Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J Carcinog 2009; 8: 3.
43. Massimi M, Devirgiliis LC,. Adhesion to the extracellular matrix is positively regulated by retinoic acid in HepG2 cells. Liver Int 2007; 27: 128-136.
44. Oertl A, Relja B, Makarevic J, Weich E, Höfler S, Jones J, Jonas D, Bratzke H, Baer PC, Blaheta RA,. Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 2006; 18: 347-354.
45. Rozzo C, Chiesa V, Ponzoni M,. Integrin up-regulation as marker of neuroblastoma cell differentiation: Correlation with neurite extension. Cell Death Differ 1997; 4: 713-724.
46. Wedel S, Hudak L, Seibel JM, Juengel E, Oppermann E, Haferkamp A, Blaheta RA,. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate 2011; 71: 722-735.
47. Goel HL, Li J, Kogan S, Languino LR,. Integrins in prostate cancer progression. Endocr Relat Cancer 2008; 15: 657-664.
48. Liu L, He B, Liu WM, Zhou D, Cox JV, Zhang XA,. Tetraspanin CD151 promotes cell migration by regulating integrin trafficking. J Biol Chem 2007; 282: 31631-31642.
49. Chen C, Zhao M, Yin N, He B, Wang B, Yuan Y, Yu F, Hu J, Yin B, Lu Q,. Abnormal Histone Acetylation and Methylation Levels in Esophageal Squamous Cell Carcinomas. Cancer Invest 2011; 29: 548-556.
50. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K,. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121: 1138-11348.
51. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM,. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 2011; 104: 1587-1593.
52. Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW,. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate 2011; 71: 232-240.
53. Puigvert JC, Huveneers S, Fredriksson L, op het Veld M, van de Water B, Danen EH,. Cross-talk between integrins and oncogenes modulates chemosensitivity. Mol Pharmacol 2009; 75: 947-955.
54. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE,. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-6279.
55. Pickl M, Ries CH,. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28: 461-468.